Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Use of product listing agreements by Canadian provincial drug benefit plans.

Morgan SG, Friesen MK, Thomson PA, Daw JR.

Healthc Policy. 2013 May;8(4):45-55.

2.
3.
4.

Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.

Morgan SG, Thomson PA, Daw JR, Friesen MK.

BMC Health Serv Res. 2013 Jan 31;13:34. doi: 10.1186/1472-6963-13-34.

5.

Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.

Demers V, Melo M, Jackevicius C, Cox J, Kalavrouziotis D, Rinfret S, Humphries KH, Johansen H, Tu JV, Pilote L.

CMAJ. 2008 Feb 12;178(4):405-9. doi: 10.1503/cmaj.070587.

6.

Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.

Hasan H, Howard F, Morgan SG, Metzger DL, Lo AC, Goddard K, Gill S, Johnson M.

Healthc Policy. 2014 Feb;9(3):80-96.

7.

A dog's breakfast: prescription drug coverage varies widely across Canada.

Anis AH, Guh D, Wang Xh.

Med Care. 2001 Apr;39(4):315-26.

PMID:
11329519
8.

Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.

Gamble JM, Weir DL, Johnson JA, Eurich DT.

CMAJ. 2011 Nov 22;183(17):E1259-66. doi: 10.1503/cmaj.110670. Epub 2011 Oct 24.

9.

Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.

Pomey MP, Morgan S, Church J, Forest PG, Lavis JN, McIntosh T, Smith N, Petrela J, Martin E, Dobson S.

J Health Polit Policy Law. 2010 Oct;35(5):705-42. doi: 10.1215/03616878-2010-025.

PMID:
21123668
10.
11.

Access to drugs for cancer: Does where you live matter?

Menon D, Stafinski T, Stuart G.

Can J Public Health. 2005 Nov-Dec;96(6):454-8.

PMID:
16350873
12.

Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.

Knowles SR, Lee K, Paterson JM, Shah BR, Mamdani MM, Juurlink DN, Gomes T.

Can J Diabetes. 2017 Apr;41(2):138-142. doi: 10.1016/j.jcjd.2016.08.225. Epub 2016 Dec 15.

13.

Common Drug Review recommendations: an evidence base for expectations?

Rocchi A, Miller E, Hopkins RB, Goeree R.

Pharmacoeconomics. 2012 Mar;30(3):229-46. doi: 10.2165/11593030-000000000-00000.

PMID:
22283689
14.

Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Daw JR, Morgan SG.

Health Policy. 2012 Jan;104(1):19-26. doi: 10.1016/j.healthpol.2011.08.015. Epub 2011 Oct 5.

15.

Cost shifting and timeliness of drug formulary decisions in atlantic Canada.

Scobie AC, Mackinnon NJ.

Healthc Policy. 2010 Feb;5(3):100-14.

16.

Targeting improved patient outcomes using innovative product listing agreements: a survey of Canadian and international key opinion leaders.

Thompson M, Henshall C, Garrison LP, Griffin AD, Coyle D, Long S, Khayat ZA, Anger DL, Yu R.

Clinicoecon Outcomes Res. 2016 Aug 26;8:427-33. doi: 10.2147/CEOR.S96616. eCollection 2016.

17.

Medicine reimbursement recommendations in Canada, Australia, and Scotland.

Lexchin J, Mintzes B.

Am J Manag Care. 2008 Sep;14(9):581-8.

18.
19.

Inter-provincial variation in government drug formularies.

Grégoire JP, MacNeil P, Skilton K, Moisan J, Menon D, Jacobs P, McKenzie E, Ferguson B.

Can J Public Health. 2001 Jul-Aug;92(4):307-12.

PMID:
11962119
20.

Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study.

Tadrous M, Martins D, Lee K, Knowles S, Mamdani MM, Juurlink DN, Gomes T.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):803-807. Epub 2016 Apr 6.

PMID:
26986676

Supplemental Content

Support Center